Industries > Pharma > Pharma Leader Series: 25 Top Biosimilar Drug Manufacturers 2017-2027

Pharma Leader Series: 25 Top Biosimilar Drug Manufacturers 2017-2027

And Other Rising Companies – a Market Report Assessing Developers and Producers of Competitor Biologics

PUBLISHED: 31 August 2017
PAGES: 233
PRODUCT CODE: PHA0231

Clear
WOOCS 2.2.1

Who Are the Leaders in the Emerging Biosimilar Drugs Market? Visiongain’s New Analysis Gives Company Assessments, Discussions and Predictions
Where are companies in the Biosimilar market heading? If you are involved in this sector you must read this brand new report. Visiongain’s report shows you the potential revenues streams to 2027, assessing data, trends, opportunities and business prospects there.

Discover how to stay ahead
Our 233-page report provides 126 tables, charts, and graphs, giving a clear view on companies in the biosimilar market. Who are the most important and promising biosimilar drug companies? And what are their sales potentials? Discover this information in our updated report, which analyses 25 leading developers, producers and marketers of biosimilars. The report also covers other firms, including big pharma companies entering that industry.

Molecules giving rise to biosimilars – explore where progress occurs
Our report discusses biosimilar competition for these five therapeutic agents – products and research and development:
• Adalimumab
• Infliximab
• Etanercept
• Darbepoetin alpha
• Rituximab.

In particular, our report analyses 25 leading biosimilar specialists worldwide. First of all, Chapter 4 gives profiles of leading biosimilar companies based in the US, Western Europe and Israel:
• Hospira (Pfizer)
• Mylan
• Sandoz (Novartis)
• STADA Arzneimittel
• Teva Pharmaceutical Industries

Chapter 5 profiles leading companies in China:
• 3SBio
• Beijing ShuangLu Pharmaceutical Co.
• Qilu Pharmaceutical
• Shanghai Fosun Pharmaceutical Group
• Tonghua Dongbao Pharmaceutical Co.

Chapter 6 profiles leading companies in India:
• Biocon
• Dr. Reddy’s Laboratories
• Intas Biopharmaceuticals
• Ranbaxy (Sun Pharma)
• Reliance Life Sciences
• Wockhardt
• Zydus Cadila

Pharma Leader Series: 25 Top Biosimilar Drug Manufacturers 2017-2027

Chapter 7 profiles leading companies in Latin America:
• Amega Biotech
• Biosidus
• Probiomed

Chapter 8 profiles leading companies in the rest of the world:
• Biocad
• Bioton
• Celltrion
• Dong-A
• LG Life Sciences

Our report also reviews 25 other companies rising in importance. See what is possible from 2017, discovering what leading companies do and their commercial outlooks.

With our report, you will see who and what shapes the biosimilars industry, including policies, regulatory concerns and other forces influencing those companies and their market, affecting its revenues and profits. Discover what the future holds for leading organisations.

How the 25 Top Biosimilar Drug Manufacturers report helps you
In summary, our 233-page report provides you with the following knowledge:
• Profiles of 25 leading biosimilar companies and other relevant firms – assess products, results, strategies, technologies and outlooks, also gaining company level revenue forecasting for five leading producers’ biosimilar drug sales
• R&D for biosimilars – see activities by company, finding what goes on in that industry, investigating its technological and commercial potentials
• Competition and opportunities – explore what affects the biosimilars market, finding what shapes its future, especially prospects for developing business

Find quantitative and qualitative analyses with independent predictions. Receive information that only our report contains, staying informed with this invaluable business intelligence.

Visiongain’s study is for everybody needing commercial analyses for the leading companies in the Biosimilar market. You will find data, trends and predictions.

Get our report today Pharma Leader Series: 25 Top Biosimilar Drug Manufacturers, 2017-2027, and Other Rising Companies – a Market Report Assessing Developers and Producers of Competitor Biologics. Avoid missing out – get our report now.

Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6

Download sample pages

Complete the form below to download your free sample pages for Pharma Leader Series: 25 Top Biosimilar Drug Manufacturers 2017-2027


Download sample pages

Complete the form below to download your free sample pages for Pharma Leader Series: 25 Top Biosimilar Drug Manufacturers 2017-2027


Latest Pharma news

Visiongain Publishes Dermatological Drugs Market Report 2021-2031

The global market for dermatological drugs is ascending and has made significant gains in skin treatments. The players in the dermatological drugs market are striving to tap the opportunities that this market offers.

18 January 2021

READ

Visiongain Publishes Antigen Skin Test Market Report to 2031

The study covers detailed and insightful chapters on market overview, market segments, new developments, competitive landscape, strategic recommendations, key company analysis, market opportunities, pricing analysis, gap analysis, porter’s 5 forces model, company profiling, geographical analysis, and analytical overview of the market. Increasing health concerns among population and growing incidences of fungal & bacterial infection are some of the factors driving the growth of Antigen Skin Test market.

12 January 2021

READ

Visiongain Publishes Anti-Infective Vaccines Market Report Report to 2031

The study covers detailed and insightful chapters on market overview, market segments, new developments, competitive landscape, strategic recommendations, key company analysis, market opportunities, pricing analysis, gap analysis, porter’s 5 forces model, company profiling, geographical analysis, and analytical overview of the market.

11 January 2021

READ

Visiongain Publishes Biological API Manufacturing Services Market Report 2021-2031

Demand in the early years of the forecast period will come from multinational biotech looking to sign deals with Indian companies and take advantage of the cheaper costs of production for the emerging market.

08 January 2021

READ

Categories

Category